Metris Therapeutics Ltd.
This article was originally published in Start Up
Executive Summary
Existing drug therapies for endometriosis, including drugs that block estrogen and GnRH agonists bear troubling side effects. Metris Therapeutics hopes to avoid these by taking a different path to the disease. The company's founders were among the first to identfiy increased levels of vascular endothelial growth factor (VEGF) in the peritoneal fluid of women with endometriosis. Metris has therfore set out to develop a product to block VEGF's action.
You may also be interested in...
Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy
Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”
The New Antibodies Revolutionizing Medicine
Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.
What Next In Oncology?
Oncology dominates pharma sales and pipeline league tables. But where is the next Keytruda?